Cervical Cancer Diagnostics Market Size, Share and Forecast (2019-2026)

SKU: DMD385 | Last Updated On: 2019-08-19 | No. of Pages: 237 | Available Formats

( 43 Samples have been requested. )
In July 2019, Roche announced its Global Access Program is expanding beyond HIV, to include Mycobacterium tuberculosis (MTB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV) for low- and middle-income country.

Cervical Cancer Diagnostics Market

Cervix is the lower part of the uterus that connects to vagina. Strains of Human Papillomavirus (HPV), a sexually transmitted infection, is responsible for 90% of cervical cancers. 13 out of 100 strains of HPV are cancerous. In cervical cancer healthy cells mutate leading to uncontrolled growth of cells. The early symptoms of cervical cancer is vaginal bleeding after sexual intercourse with excruciating pain, irregular or intermenstrual vaginal bleeding, lower back, leg or pelvic pain, fatigue, weight loss, loss of appetite, vaginal discomfort or odorous discharge and a single swollen leg.
The global cervical cancer diagnostics market size was worth $ XX billion in 2018 and is forecasted to reach $ XX billion by 2026, at a CAGR of XX% during the forecast period (2019-2026).
Global Cervical Cancer Diagnostics Market Value (USD Mn), 2018-2026

Cervical Cancer Diagnostics Market Dynamics

The cervical cancer diagnostics market growth is driven by several factors such as increased prevalence of cervical cancer, proactive initiatives by various government and non-government organizations, awareness among people, technological advancements and improvement in healthcare infrastructure.
According to the World Health Organization (WHO) in 2018, cervical cancer was the fourth most frequent cancer in women with an estimated 570,000 new cases representing 6.6% of all female cancers. The rise in cervical cancer is due to increase in number of female smokers and rise in cases of unsafe sex. The cases of cervical cancer are higher in developing countries due to lack of early and proper detection of cancer. Lack of immunity is also one of the factor responsible for higher risk of developing cervical cancer.
Various organizations are working towards creating awareness among general population and elimination of cervical cancer. UN has launched a Joint Global Programme on Cervical Cancer Prevention and Control in 2013 to achieve global elimination of cervical cancer by providing technical assistance and resources for the early diagnosis and treatment. Several countries have joined UN in this mission. Many government organizations such as Centre for Disease Control and Prevention (CDC) has a National Breast and Cervical Cancer Early Detection Program (NBCCEDP) that provides cervical cancer screenings and diagnostic services to low-income, uninsured, and underinsured women across the United States. Similarly, Medicaid also has a Breast and Cervical Cancer Control Program that provides cervical cancer screening and diagnostics to women who are below 250% of the Federal Poverty Guidelines.
There are various technological advancements in the diagnostics of cervical cancer. Many companies are coming up with new, easier, and faster ways to improve outcomes. For instance, Eve Medical Inc., a company based in Canada has launches a self-collecting vaginal swab and optional mailer box known as HerSwab that enables to collect own samples from vagina/cervix, place it in a transport bag and mail it for molecular testing. HerSwab is approved by Health Canada and for use in European Union. Similarly, an Israeli startup Biop Medical has created an FDA approved system that is in sterile disposable cover and can be safely inserted in patient’s cervix where an algorithm directs a high-definition, digital colposcope to the center of the cervix, which emits light and receive its reflection. The light reflected by the cervical tissue indicates the location of any cancerous or pre-cancerous lesions.
Primary healthcare facilities where preventive healthcare such as cervical screening and diagnostic tools should be present are limited, under-resourced and over-burdened in most developing countries. Most of the low-resource countries have very limited cancer diagnostic services available in palliative care. One of the major reason for this lack of primary healthcare is illiteracy and over population.

Cervical Cancer Diagnostics Market Segment Analysis

By test type, the global cervical cancer diagnostics market is segmented into pap smear test, HPV DNA test and colposcopy. Among these pap smear test is expected to account for the largest market share during the forecast period (2019-2026), owing to its ability to detect cervical cancer at an early stage. Pap smear test gives a better chance of cure due to early diagnosis. A Pap smear can also detect changes in your cervical cells that suggest cancer may develop in the future. The Pap smear is usually done in conjunction with a pelvic exam. In women older than age 30, the Pap test may be combined with a test for human papillomavirus (HPV) — a common sexually transmitted infection that can cause cervical cancer. As per data given by Centers for Medicare and Medicaid Services (CMS), the number of women who took pap smear test in 2017 in U.S. varies for different age groups. Before the age of 21, 60% of women were screened, between 75-79, 53% and 38% of above 80 years. The cervical cancer death rate has dropped significantly with the increased use of pap smear test.
Based on age group, the market is segmented into below 21, 21-29, 30-65 and 65 and older. The target age group of cervical cancer is 30-65 years and screening should be performed at least once every year for women in this age group. This age group is usually expected to get at least one test or a combination of tests such as pap smear and HPV more frequently. The risk of getting cervical cancer increases with increase in age.

Cervical Cancer Diagnostics Market Geographical Share

North America is dominating the cervical cancer diagnostics market in 2018 and estimated to hold largest market size over the forecast period (2019-2026), owing to rise in cases of cervical cancer, increase in female population, rising awareness among population regarding cervical cancer and favourable reimbursement policies. As per data collected by U.S. Health and Human Services the incidence rate for cervical cancer was 8.1 cases per 100,000 women per year in the US. FDA has approved HPV DNA testing in conjunction with pap smear test for routine cervical screening of women 30 years of age and older. There is additional development of screening tests in U.S. for examining additional markers of HPV infection. U.S. government provides insurance and reimbursement for cervical screening through Medicaid and supporting efforts to make cervical cancer prevention, screening, and treatment more affordable to help reduce cervical cancer incidence and mortality.
Asia-Pacific is expected to grow at the highest CAGR over the period of forecast due to high population base, development in healthcare infrastructure, and increase in government initiatives. According to American Association of Cancer Research Asia-Pacific region contributes to more than 50% of cervical cancer cases worldwide. Government initiatives such as in Australia where the commencement of a well-organized Pap program in 1991 and 2005 reduced the incidence of cervical cancer in women of all ages decreased from 12.7 to 6.9 of 100,000.

Global Cervical Cancer Diagnostics Market Share (%), By Geography, 2018

Cervical Cancer Diagnostics Market Competitive Landscape

Some of the major key players in the market are Abbott Laboratories, Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Guided Therapeutics, Olympus, Cardinal Health, Siemens Healthcare, Hologic, Inc., Quest Diagnostics, QIAGEN,  OncoHealth Corp., Arbor Vita,  Zilico Ltd.
In the cervical cancer diagnostics market, Abbott Laboratories and F. Hoffmann-La Roche Ltd. holds the leadership position. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the cervical cancer diagnostics market globally.
In November 2018, Qiagen launched QIAscreen HPV PCR Test, a CE-IVD marked molecular diagnostic test for the detection of 15 recognized high-risk genotypes of human papillomavirus.
In April 2017, US Food and Drug Administration (FDA) gave 510(k) clearance for the CINtec® Histology test. This test is the only clinically validated p16 biomarker test that, when used in conjunction with hematoxylin & eosin (H&E) staining, helps pathologists determine which women should receive treatment for cervical pre-cancer.

Why Purchase the Report?

  • Visualize the composition of the cervical cancer diagnostics market across each indication, in terms of type and by type highlighting the key commercial assets and players.
  • Identify commercial opportunities in cervical cancer diagnostics by analyzing trends and co-development deals.
  • Excel data sheets with thousands of data points of cervical cancer diagnostics market-level 4/5 segmentation.
  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key products of all major market players.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers
     

Cervical Cancer Diagnostics Market

  1. Global Cervical Cancer Diagnostics Market Methodology and Scope

    1. Research Methodology

    2. Research Objective and Scope of the Report

  2. Global Cervical Cancer Diagnostics Market – Market Definition and Overview

  3. Global Cervical Cancer Diagnostics Market – Executive Summary

    1. Market Snippet by Test Type

    2. Market Snippet by Age Group

    3. Market Snippet by Region

    4. DataM CLO Scenario

  4. Global Cervical Cancer Diagnostics Market Dynamics

    1. Market Impacting Factors

      1. Drivers

        1. Increased prevalence of cervical cancer

        2. Proactive initiatives by various government and non-government organizations

        3. Awareness among people

        4. Technological advancements

        5. Improvement in healthcare infrastructure

      2. Restraints

        1. High cost of cervical cancer diagnostics procedures

        2. Lack of awareness in developing countries

      3. Opportunity

      4. Impact Analysis

  5. Global Cervical Cancer Diagnostics Market – Industry Analysis

    1. Porter's Five Forces Analysis

    2. Supply Chain Analysis

    3. Regulatory Analysis

    4. Epidemiology

  6. Global Cervical Cancer Diagnostics Market – By Test Type

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type

      2. Market Attractiveness Index, By Test Type

    2. PAP Smear Test

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

    3. HPV DNA Test

    4. Coloscopy

  7. Global Cervical Cancer Diagnostics Market – By Age Group

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group

      2. Market Attractiveness Index, By Age Group

    2. Below 21

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026

    3. 21-29

    4. 30-65

    5. 65 and above

  8. Global Cervical Cancer Diagnostics Market – By Region

    1. Introduction

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

      2. Market Attractiveness Index, By Region

    2. North America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. U.S.

        2. Canada

        3. Mexico

    3. Europe

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. Germany

        2. U.K.

        3. France

        4. Italy

        5. Spain

        6. Rest of Europe

    4. South America

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

      6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. Brazil

        2. Argentina

        3. Rest of South America

    5. Asia-Pacific

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group

      5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

        1. China

        2. India

        3. Japan

        4. Australia

        5. Rest of Asia Pacific

    6. Middle East and Africa

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Age Group

  9. Global Cervical Cancer Diagnostics Market – Competitive Landscape

    1. Competitive Scenario

    2. Competitor Cervical Cancer Diagnostics Strategy Analysis

    3. Comparative Product Portfolio Analysis

    4. Market Positioning/Share Analysis

    5. Mergers and Acquisitions Analysis

  10. Company Profiles

    1. Abbott Laboratories *

      1. Company Overview

      2. Product Portfolio and Description

      3. Key Highlights

      4. Financial Overview

    2. Becton, Dickinson and Company

    3. F. Hoffmann-La Roche Ltd.

    4. Guided Therapeutics

    5. Olympus

    6. Cardinal Health

    7. Siemens Healthcare

    8. Hologic, Inc.

    9. Quest Diagnostics

    10. QIAGEN

    11. OncoHealth Corp.

    12. Arbor Vita

    13. Zilico Ltd.

  11. Global Cervical Cancer Diagnostics Market – Premium Insights

  12. Global Cervical Cancer Diagnostics Market – DataM

    1. Appendix

    2. About Us and Services

    3. Contact Us

List of Tables
Table 1    Global Cervical Cancer Diagnostics Market Value, By Test Type, 2018,2022 & 2026 ($ Million)
Table 2    Global Cervical Cancer Diagnostics Market Value, By Age Group, 2018,2022 & 2026 ($ Million)
Table 3    Global Cervical Cancer Diagnostics Market Value, By Region, 2018,2022 & 2026 ($ Million)
Table 4    Global Cervical Cancer Diagnostics Market Value, By Test Type, 2018,2022 & 2026 ($ Million)
Table 5    Global Cervical Cancer Diagnostics Market Value, By Test Type, 2017-2026 ($ Million)
Table 6    Global Cervical Cancer Diagnostics Market Value, By Age Group, 2018,2022 & 2026 ($ Million)
Table 7    Global Cervical Cancer Diagnostics Market Value, By Age Group, 2017-2026 ($ Million)
Table 8    Global Cervical Cancer Diagnostics Market Value, By Region, 2018,2022 & 2026 ($ Million)
Table 9    Global Cervical Cancer Diagnostics Market Value, By Region, 2017-2026 ($ Million)
Table 10    North America Cervical Cancer Diagnostics Market Value, By Test Type, 2017-2026 ($ Million)
Table 11    North America Cervical Cancer Diagnostics Market Value, By Age Group, 2017-2026 ($ Million)
Table 12    North America Cervical Cancer Diagnostics Market Value, By Country, 2017-2026 ($ Million)
Table 13    South America Cervical Cancer Diagnostics Market Value, By Test Type, 2017-2026 ($ Million)
Table 14    South America Cervical Cancer Diagnostics Market Value, By Age Group, 2017-2026 ($ Million)
Table 15    South America Cervical Cancer Diagnostics Market Value, By Country, 2017-2026 ($ Million)
Table 16    Europe Cervical Cancer Diagnostics Market Value, By Test Type, 2017-2026 ($ Million)
Table 17    Europe Cervical Cancer Diagnostics Market Value, By Age Group, 2017-2026 ($ Million)
Table 18    Europe Cervical Cancer Diagnostics Market Value, By Country, 2017-2026 ($ Million)
Table 19    Asia-Pacific Cervical Cancer Diagnostics Market Value, By Test Type, 2017-2026 ($ Million)
Table 20    Asia-Pacific Cervical Cancer Diagnostics Market Value, By Age Group, 2017-2026 ($ Million)
Table 21    Asia-Pacific Cervical Cancer Diagnostics Market Value, By Country, 2017-2026 ($ Million)
Table 22    Middle East & Africa Cervical Cancer Diagnostics Market Value, By Test Type, 2017-2026 ($ Million)
Table 23    Middle East & Africa Cervical Cancer Diagnostics Market Value, By Age Group, 2017-2026 ($ Million)
Table 24    Abbott Laboratories: Overview
Table 25    Abbott Laboratories: Product Portfolio
Table 26    Abbott Laboratories: Key Developments
Table 27    Becton, Dickinson and Company: Overview
Table 28    Becton, Dickinson and Company: Product Portfolio
Table 29    Becton, Dickinson and Company: Key Developments
Table 30    Guided Therapeutics: Overview
Table 31    Guided Therapeutics: Product Portfolio
Table 32    Guided Therapeutics: Key Developments
Table 33    Olympus: Overview
Table 34    Olympus: Product Portfolio
Table 35    Olympus: Key Developments
Table 36    Cardinal Health: Overview
Table 37    Cardinal Health: Product Portfolio
Table 38    Cardinal Health: Key Developments
Table 39    Siemens Healthcare: Overview
Table 40    Siemens Healthcare: Product Portfolio
Table 41    Siemens Healthcare: Key Developments
Table 42    Hologic, Inc.: Overview
Table 43    Hologic, Inc.: Product Portfolio
Table 44    Hologic, Inc.: Key Developments
Table 45    Quest Diagnostics: Overview
Table 46    Quest Diagnostics: Product Portfolio
Table 47    Quest Diagnostics: Key Developments
Table 48    QIAGEN: Overview
Table 49    QIAGEN: Product Portfolio
Table 50    QIAGEN: Key Developments
Table 51    OncoHealth Corp.: Overview
Table 52    OncoHealth Corp.: Product Portfolio
Table 53    OncoHealth Corp.: Key Developments

List of Figures
Figure 1    Global Cervical Cancer Diagnostics Market Share, By Test Type, 2018 & 2026 (%)
Figure 2    Global Cervical Cancer Diagnostics Market Share, By Age Group, 2018 & 2026 (%)
Figure 3    Global Cervical Cancer Diagnostics Market Share, By Region, 2018 & 2026 (%)
Figure 4    Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 5    Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Test Type, 2018-2026 (%)
Figure 6    PAP Smear Test: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 7    HPV DNA Test: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 8    Coloscopy: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 9    Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Age Group, 2018-2026 (%)
Figure 10    Below 21: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 11    21-29: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 12    30-65: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 13    65 and above: Global Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 14    Global Cervical Cancer Diagnostics Market Y-o-Y Growth, By Region, 2018-2026 (%)
Figure 15    North America Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 16    North America Cervical Cancer Diagnostics Market Share, By Test Type, 2018 & 2026 (%)
Figure 17    North America Cervical Cancer Diagnostics Market Share, By Age Group, 2018 & 2026 (%)
Figure 18    North America Cervical Cancer Diagnostics Market Share, By Country, 2018 & 2026 (%)
Figure 19    South America Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 20    South America Cervical Cancer Diagnostics Market Share, By Test Type, 2018 & 2026 (%)
Figure 21    South America Cervical Cancer Diagnostics Market Share, By Age Group, 2018 & 2026 (%)
Figure 22    South America Cervical Cancer Diagnostics Market Share, By Country, 2018 & 2026 (%)
Figure 23    Europe Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 24    Europe Cervical Cancer Diagnostics Market Share, By Test Type, 2018 & 2026 (%)
Figure 25    Europe Cervical Cancer Diagnostics Market Share, By Age Group, 2018 & 2026 (%)
Figure 26    Europe Cervical Cancer Diagnostics Market Share, By Country, 2018 & 2026 (%)
Figure 27    Asia-Pacific Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 28    Asia-Pacific Cervical Cancer Diagnostics Market Share, By Test Type, 2018 & 2026 (%)
Figure 29    Asia-Pacific Cervical Cancer Diagnostics Market Share, By Age Group, 2018 & 2026 (%)
Figure 30    Asia-Pacific Cervical Cancer Diagnostics Market Share, By Country, 2018 & 2026 (%)
Figure 31    Middle East & Africa Cervical Cancer Diagnostics Market Value, 2017-2026 ($ Million)
Figure 32    Middle East & Africa Cervical Cancer Diagnostics Market Share, By Test Type, 2018 & 2026 (%)
Figure 33    Middle East & Africa Cervical Cancer Diagnostics Market Share, By Age Group, 2018 & 2026 (%)
Figure 34    Abbott Laboratories: Financials
Figure 35    Becton, Dickinson and Company: Financials
Figure 36    Guided Therapeutics: Financials
Figure 37    Olympus: Financials
Figure 38    Cardinal Health: Financials
Figure 39    Siemens Healthcare: Financials
Figure 40    Hologic, Inc.: Financials
Figure 41    Quest Diagnostics: Financials
Figure 42    QIAGEN: Financials
Figure 43    OncoHealth Corp.: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report